Neuroendocrine differentiation in prostatic carcinomas. A retrospective autospy study

E. A. Turbat-Herrera, G. A. Herrera, I. Gore, R. L. Lott, W. E. Grizzle, Jose Bonnin

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Neuroendocrine differentiation in prostatic neoplasms has in the past been considered extremely uncommon. The histologic neuroendocrine patterns reported previously vary from small cell to carcinoidlike to mixed adenocarcinoma-small cell or carcinoid. The majority of the tumors reported are of the mixed variety. We reviewed 2648 autopsies, revealing 69 prostatic carcinomas, eight with neuroendocrine differentiation (five mixed adenocarcinoma-small-cell carcinoma, two 'pure' small cell, and one 'pure' carcinoidlike). The mean patient age was 69.5 years. One patient presented with markedly elevated serum corticotropin and another was severely hypercalcemic with elevated serum parathyroid hormone level. Three neoplasms were incidental autopsy findings. The mean survival time, after diagnosis, was 19 months for the other patients. Three of the cases were examined ultrastructurally and showed cytoplasmic processes containing membrane-bound granules in the neuroendocrine component. The areas with neuroendocrine differentiation were positive for markers as follows: neuron-specific enolase, seven of eight; prostate-specific antigen (PSA), none of eight; chromogranin A, seven of eight; synaptophysin, four of eight; and calcitonin, four of eight. Those neoplasms mixed with an adenocarcinoma component showed well-defined PSA positivity in the glandular elements. This study suggests that neuroendocrine differentiation in prostatic neoplasms may be more common than previously thought. Often, the areas with neuroendocrine differentiation are considered to represent poorly differentiated adenocarcinoma. It is important to recognize neuroendocrine components in prostatic carcinomas owing to prognostic and potential therapeutic implications.

Original languageEnglish (US)
Pages (from-to)1100-1105
Number of pages6
JournalArchives of Pathology and Laboratory Medicine
Volume112
Issue number11
StatePublished - 1988
Externally publishedYes

Fingerprint

Adenocarcinoma
Retrospective Studies
Carcinoma
Prostate-Specific Antigen
Autopsy
Prostatic Neoplasms
Chromogranin A
Neoplasms
Synaptophysin
Incidental Findings
Small Cell Carcinoma
Phosphopyruvate Hydratase
Carcinoid Tumor
Calcitonin
Parathyroid Hormone
Serum
Adrenocorticotropic Hormone
Survival Rate
Membranes
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Turbat-Herrera, E. A., Herrera, G. A., Gore, I., Lott, R. L., Grizzle, W. E., & Bonnin, J. (1988). Neuroendocrine differentiation in prostatic carcinomas. A retrospective autospy study. Archives of Pathology and Laboratory Medicine, 112(11), 1100-1105.

Neuroendocrine differentiation in prostatic carcinomas. A retrospective autospy study. / Turbat-Herrera, E. A.; Herrera, G. A.; Gore, I.; Lott, R. L.; Grizzle, W. E.; Bonnin, Jose.

In: Archives of Pathology and Laboratory Medicine, Vol. 112, No. 11, 1988, p. 1100-1105.

Research output: Contribution to journalArticle

Turbat-Herrera, EA, Herrera, GA, Gore, I, Lott, RL, Grizzle, WE & Bonnin, J 1988, 'Neuroendocrine differentiation in prostatic carcinomas. A retrospective autospy study', Archives of Pathology and Laboratory Medicine, vol. 112, no. 11, pp. 1100-1105.
Turbat-Herrera, E. A. ; Herrera, G. A. ; Gore, I. ; Lott, R. L. ; Grizzle, W. E. ; Bonnin, Jose. / Neuroendocrine differentiation in prostatic carcinomas. A retrospective autospy study. In: Archives of Pathology and Laboratory Medicine. 1988 ; Vol. 112, No. 11. pp. 1100-1105.
@article{2cdba51664b048279ae8365280b8ba55,
title = "Neuroendocrine differentiation in prostatic carcinomas. A retrospective autospy study",
abstract = "Neuroendocrine differentiation in prostatic neoplasms has in the past been considered extremely uncommon. The histologic neuroendocrine patterns reported previously vary from small cell to carcinoidlike to mixed adenocarcinoma-small cell or carcinoid. The majority of the tumors reported are of the mixed variety. We reviewed 2648 autopsies, revealing 69 prostatic carcinomas, eight with neuroendocrine differentiation (five mixed adenocarcinoma-small-cell carcinoma, two 'pure' small cell, and one 'pure' carcinoidlike). The mean patient age was 69.5 years. One patient presented with markedly elevated serum corticotropin and another was severely hypercalcemic with elevated serum parathyroid hormone level. Three neoplasms were incidental autopsy findings. The mean survival time, after diagnosis, was 19 months for the other patients. Three of the cases were examined ultrastructurally and showed cytoplasmic processes containing membrane-bound granules in the neuroendocrine component. The areas with neuroendocrine differentiation were positive for markers as follows: neuron-specific enolase, seven of eight; prostate-specific antigen (PSA), none of eight; chromogranin A, seven of eight; synaptophysin, four of eight; and calcitonin, four of eight. Those neoplasms mixed with an adenocarcinoma component showed well-defined PSA positivity in the glandular elements. This study suggests that neuroendocrine differentiation in prostatic neoplasms may be more common than previously thought. Often, the areas with neuroendocrine differentiation are considered to represent poorly differentiated adenocarcinoma. It is important to recognize neuroendocrine components in prostatic carcinomas owing to prognostic and potential therapeutic implications.",
author = "Turbat-Herrera, {E. A.} and Herrera, {G. A.} and I. Gore and Lott, {R. L.} and Grizzle, {W. E.} and Jose Bonnin",
year = "1988",
language = "English (US)",
volume = "112",
pages = "1100--1105",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "11",

}

TY - JOUR

T1 - Neuroendocrine differentiation in prostatic carcinomas. A retrospective autospy study

AU - Turbat-Herrera, E. A.

AU - Herrera, G. A.

AU - Gore, I.

AU - Lott, R. L.

AU - Grizzle, W. E.

AU - Bonnin, Jose

PY - 1988

Y1 - 1988

N2 - Neuroendocrine differentiation in prostatic neoplasms has in the past been considered extremely uncommon. The histologic neuroendocrine patterns reported previously vary from small cell to carcinoidlike to mixed adenocarcinoma-small cell or carcinoid. The majority of the tumors reported are of the mixed variety. We reviewed 2648 autopsies, revealing 69 prostatic carcinomas, eight with neuroendocrine differentiation (five mixed adenocarcinoma-small-cell carcinoma, two 'pure' small cell, and one 'pure' carcinoidlike). The mean patient age was 69.5 years. One patient presented with markedly elevated serum corticotropin and another was severely hypercalcemic with elevated serum parathyroid hormone level. Three neoplasms were incidental autopsy findings. The mean survival time, after diagnosis, was 19 months for the other patients. Three of the cases were examined ultrastructurally and showed cytoplasmic processes containing membrane-bound granules in the neuroendocrine component. The areas with neuroendocrine differentiation were positive for markers as follows: neuron-specific enolase, seven of eight; prostate-specific antigen (PSA), none of eight; chromogranin A, seven of eight; synaptophysin, four of eight; and calcitonin, four of eight. Those neoplasms mixed with an adenocarcinoma component showed well-defined PSA positivity in the glandular elements. This study suggests that neuroendocrine differentiation in prostatic neoplasms may be more common than previously thought. Often, the areas with neuroendocrine differentiation are considered to represent poorly differentiated adenocarcinoma. It is important to recognize neuroendocrine components in prostatic carcinomas owing to prognostic and potential therapeutic implications.

AB - Neuroendocrine differentiation in prostatic neoplasms has in the past been considered extremely uncommon. The histologic neuroendocrine patterns reported previously vary from small cell to carcinoidlike to mixed adenocarcinoma-small cell or carcinoid. The majority of the tumors reported are of the mixed variety. We reviewed 2648 autopsies, revealing 69 prostatic carcinomas, eight with neuroendocrine differentiation (five mixed adenocarcinoma-small-cell carcinoma, two 'pure' small cell, and one 'pure' carcinoidlike). The mean patient age was 69.5 years. One patient presented with markedly elevated serum corticotropin and another was severely hypercalcemic with elevated serum parathyroid hormone level. Three neoplasms were incidental autopsy findings. The mean survival time, after diagnosis, was 19 months for the other patients. Three of the cases were examined ultrastructurally and showed cytoplasmic processes containing membrane-bound granules in the neuroendocrine component. The areas with neuroendocrine differentiation were positive for markers as follows: neuron-specific enolase, seven of eight; prostate-specific antigen (PSA), none of eight; chromogranin A, seven of eight; synaptophysin, four of eight; and calcitonin, four of eight. Those neoplasms mixed with an adenocarcinoma component showed well-defined PSA positivity in the glandular elements. This study suggests that neuroendocrine differentiation in prostatic neoplasms may be more common than previously thought. Often, the areas with neuroendocrine differentiation are considered to represent poorly differentiated adenocarcinoma. It is important to recognize neuroendocrine components in prostatic carcinomas owing to prognostic and potential therapeutic implications.

UR - http://www.scopus.com/inward/record.url?scp=0023734347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023734347&partnerID=8YFLogxK

M3 - Article

C2 - 2460064

AN - SCOPUS:0023734347

VL - 112

SP - 1100

EP - 1105

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 11

ER -